The role of supportive therapy in the era of modern adjuvant treatment- Current and future tools

Breast Care

Volumn 4, Issue 3, 2009, Pages 167-176

  Bartsch, Rupert ^a   Steger, Guenther G ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Adjuvant treatment; Breast cancer; Growth factors; Side effects; Supportive care

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; APREPITANT; CAPECITABINE; CHLORHEXIDINE; CIPROFLOXACIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERYTHROPOIETIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; KERATINOCYTE GROWTH FACTOR; METHOTREXATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OCTREOTIDE; ONDANSETRON; PACLITAXEL; PLACEBO; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEROTONIN 3 ANTAGONIST; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; BLOOD TRANSFUSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LOW DRUG DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; OSTEOPOROSIS; PAIN; POLYNEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 67651121720     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000223360     Document Type: Review

References (98)

1. Coiffer B, Guastella J P, Pujade-Lauraine E, et al.: Anemia Study Group. Predicting cancer-associated anemia in patients receiving non-platinum chemotherapy: results of a prospective survey. Eur J Cancer 2001;37:1617-1623.
2. Ludwig H, Van Belle S, Barrett-Lee P, et al.: The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J cancer 2004;40:2293-2306.
3. Montserrat E, Bosch F, Rozman C: B-cell chronic lymphatic leukemia: recent progress in biology, diagnosis, and therapy. Ann Oncol 1997;8(suppl 1): 93s-101s.
4. Mecadante S, Gebbia V, Marrazzo A, et al.: Anemia in cancer: pathophysiology and treatment. Cancer Treat Rev 2000;26:303-311.
5. Groopman JE, Itri LM: Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-1634.
6. Barrett-Lee PJ, Bailey NP, O'Brien ME, et al.: Large-scale UK audit of blood transfusions requirements and anaemia in patients receiving cytotoxic chemotherapy. Brit J Cancer 2000;82:93-97.
7. Grotto HZ: Anaemia of cancer: an overview of mechanisms involved in its pathogenesis. Med Oncol 2008;25:12-21.
8. Stone P, Richardson A, Ream E, et al.: Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol 2000;11:971-975.
9. Curt GA: Impact of fatigue on quality of life in oncology patients. Semin Hematol 2003;37(suppl 6): 14s-17s.
10. Tchekmediyan NS, Kallich J, McDermott A: The relationship between psychologic distress and cancer related fatigue. Cancer 2003;98:198-203.
11. Tchekmedyian NS: Anemia in cancer patients: significance, epidemiology, and current therapy. Oncology 2002;16:17-24.
12. Food and Drug Administration: Information for healthcare professionals: erythropoiesis stimulating agents (ESA) (Arenesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa)). www.fda. gov/SiteIndex/ucm126485.htm.
13. Bohlius J, Schmidlin K, Brillant C, et al.: Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a metaanalysis of randomised trials. Lancet 2009;373: 1532-1542.
14. Miller CB, Jones RJ, Piantadosi S, et al.: Decreased erythropoietin response in patients with anaemia of cancer. N Engl J Med 1990;322:1689-1692.
15. Food and Drug Administration: Oncologic Drugs Advisory Committee Briefing Document. Safety Concerns Associated with Aranesp (darbeopoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.P., for the Treatment of Anemia Associated with Cancer Chemotherapy. www.fda.gov/ ohrms/dockets/ac/04/ briefing/4037b2-04.pdf.
16. Seidenfeld J, Piper M, Flamm C, et al.: Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001; 93:1204-1214.
17. Littlewood TJ, Bajetta E, Nortier JW, et al.: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
18. Dellinger EP, Anaya DE: Infectious and immunologic consequences of blood transfusion. Critical Care 2004;8(suppl 2):18S-23S.
19. Leyland-Jones B, Semiglazov V, Pawlicki M, et al.: Maintaining normal haemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2007;25:1027-1032.
20. Henke M, Laszig R, Rübe C, et al.: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, doubleblind, placebo-controlled trial. Lancet 2003;362: 1255-1260.
21. Wright JR, Ung YC, Julian JA, et al.: Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with diseaserelated anaemia. J Clin Oncol 2007;25:1027-1032.
22. Goldberg P: Danish researchers post long-awaited Aranesp results - ever so discreetly. Cancer Lett 2007;33:1-6.
23. Food and Drug Administration: Oncologic Drugs Advisory Committee Briefing Document. www.fda. gov/ohrms/dockets/ac/07/briefing/2007-4301b2-00-index. htm.
24. Seminara P, Minutoli L, Torre V, et al.: Recombinant human erythropoietin stimulates angiogenesis and wound healing in genetically diabetic mouse. Diabetes 2004; 53:2509-2517.
25. George C, Goldstein E, Abashidze A, et al.: Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI3-kinase-dependent manner. Cardiovascular Res 2005; 68:299-306.
26. Longmore GD: Do cancer cells express functional erythropoietin receptor? N Engl J Med 2007; 356:2447.
27. Smith TJ, Khatcheressian J, Lyman GH, et al.: 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24: 3187-3205.
28. Crivellari D, Bonetti M, Castiglione-Gertsch M, et al.: Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII. J Clin Oncol 2000;18:1412-1422.
29. Dees EC, O'Reilly S, Goodman SN, et al.: A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest 2000;18:521-529.
30. Gelam RS, Taylor SG: Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: The elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 1984;2:1404-1413.
31. Goldhirsch A, Colleoni M, Coates AS, et al.: Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? Ann Oncol 1998;9:489-493.
32. Citron ML, Berry DA, Cirrincione C, et al.: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-1439.
33. Dang C, Fornier M, Sugarman S, et al.: The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER2/neu overexpressed/amplified breast cancer. J Clin Oncol 2008;26:1216-1222.
34. Fornier MN, Seidman AD, Lake D, et al.: Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer. Clin Cancer Res 2007;13:223-227.
35. Yerushalmi R, Kramer MR, Rizel S, et al.: Decline in pulmonary function in patients with breast cancer receiving dose-dense chemotherapy: a prospective study. Ann Oncol 2009;20:437-440.
36. Nabholtz JM, Riva A: Taxane/anthracycline combinations: setting a new standard in breast cancer? Oncologist 2001;6(suppl 3):5s-12s.
37. Steger GG, Galid A, Gnant M, et al.: Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14. J Clin Oncol 2007;25:2012-2018.
38. Wenzel C, Bartsch R, Locker GJ, et al.: Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer. Anticancer Drugs 2005;16:441-445.
39. Von Minckwitz G, Kümmel S, du Bois A, et al.: Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclo- phosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol 2008;19:292-298.
40. Smith RE, Bryant J, DeCillis A, et al.: Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 2003;21:1195-1204.
41. Hershman D, Neugut AI, Jacobson JS, et al.: Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. Natl Cancer Inst 2007;99:196-205.
42. Link H, Boehme A, Cornely OA, et al.: Antimicrobial therapy of unexplained fever in neutropenic patients. Ann Haematol 2003;82(suppl 3): 105S-117S.
43. American Cancer Society: www.cancer.org/doc-root/ETO/content/ETO-1-2X- Infections-in-Peo-ple-with-Cancer.asp.
44. NCCN: www.nccn.org/professionals/physician-gls/ PDF/infections.pdf.
45. Kris MG, Hesketh PJ, Somerfield MR, et al.: American Society of Clinical Oncology Guideline for An-tiemetics in Oncology: update 2006. J Clin Oncol 2006;24:2932-2947.
46. Benson AB, AjaniJA, Catalano RB, et al.: Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004; 22:2918-2926.
47. Keefe DM, Schubert MM, Elting LS, et al.: Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007;109:820-831.
48. Higa GM, Auber ML, Altaha R, et al.: 5-Hydro-xyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy. J Oncol Pharm Pract. 2006;12:201-209.
49. Navari RM, Reinhardt RR, Gralla RJ, et al.: Reduction of cisplatin-induced emesis by a selective neu-rokinin-1-receptor antagonist. N Engl J Med 1999; 340:190-195.
50. Chwala S P, Grunberg SM, Gralla RJ, et al.: Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003;97:2290-2230.
51. Warr DG, Grunburg SM, Gralla RJ, et al.: The oral NK(1) antagonist aprepitant fort he prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised double-blind, placebo controlled trials. Eur J Cancer 2005;41:1278-1285.
52. Warr DG, Hesketh PJ, Gralla RJ, et al.: Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;97: 2822-2800.
53. Ngyen P, Hande K, Petty KJ, et al.: Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol 2005; 55:609-616.
54. Keefe DM: Mucositis management in patients with cancer. Support Cancer Ther 2006;3:154-157.
55. Sonis ST, Elting LS, Keefe D, et al.: Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology and consequences for patients. Cancer 2004;23:6-9.
56. Jones JA, Avritscher EBC, Cooksley CD, et al.: Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer 2006;14:505-515.
57. Ulrich CM, Yasui Y, Storb R, et al.: Pharmacogenet-ics of methotrexate: toxicity among marrow transplantation patients varies with methylenetetrahydro- folate reductase C667T polymorphism. Blood 2001; 98:231-234.
58. Rubenstein EB, Peterson DE, Schubert M, et al.: Clinical practice guidelines fort he prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004;100(suppl 9): 2026s-2046s.
59. Cheng KK, Molassiotis A, Chang AM, et al.: Evaluation of an oral care protocol intervention in the prevention of chemotherapy-induced oral mucositis in paediatric cancer patients. Eur J Cancer 2001; 37:2056-2063.
60. Dodd MJ, Dibble SL, Miaskowski C, et al.: Randomized clinical trial of the effectiveness of 3 commonly used mouth-washes to treat chemotherapyinduced mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;90:39-47.
61. Spielberger R, Stiff P, Bensinger W, et al.: Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004;351: 2590-2598.
62. Valcarcel D, Sanz MA, Sureda A, et al.: Mouth-washings with recombinant human granulozyte-macro-phage colony stimulating factor (rhGM-CSF) do not improve grade III-IV oropharyngeal mucositis (OM) in patients with haematological malignancies undergoing stem cell transplantation. Results of a randomized double-blind placebo-controlled study. Bone Marrow Transplant 2002;29:783-787.
63. Richardson G, Dobish R: Chemotherapy induced diarrhea. J Oncol Pharm Pract 2007;13:181-198.
64. Arbuckle RB, Hubr SL, Zacker C, et al.: The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study. Oncologist 2000;5:250-259.
65. Rothenberg ML, Meropol NJ, Poplin EA, et al.: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001;19:3801-3807
66. Saltz LB, Cox J V, Blande C, et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-914.
67. Stemmler HJ, Kenngotte S, Diepolder H, et al.: Gastrointestinal toxicity associated with weekly docetaxel treatment. Ann Oncol 2002;13:978-981.
68. Ibrahim NK, Sahin AA, Dubrow RA, et al.: Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet 2000;355:281-283.
69. Wadler S, Haynes H, Wiernik PH: Phase I trial of somatostatin analog octreotide acetate in the treatment of fluoropyrimidine.induced diarrhea. J Clin Oncol 1995;13:222-226.
70. Goumas P, Naxakis S, Christopoulou A, et al.: Octreotide acetate in the treatment of fluorouracil induced diarrhea. Oncologist 1998;3:50-53.
71. Hines SL, Mincey BA, Sloan JA, et al.: Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol 2009; 27:1047-1053.
72. Hershman DL, McMahon DJ, Crew KD, et al.: Zoledronic acid prevents bone loss in premeno-pausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2008; 26:4739-4745.
73. Gnant M, Mlineritsch B, Schippinger W, et al.: Endocrine therapy plus zoledronic acid in pre-menopausal breast cancer. N Engl J Med 2009;360: 679-691.
74. Lee JJ, Swain SM.: Peripheral neuropathy induced by microtubule- stabilizing agents. J Clin Oncol 2006;24:1633-1642.
75. Ocean AJ, Vahdat LT: Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer 2004;12:619-25.
76. Wolf S, Barton D, Kottschade L, et al.: Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 2008;44:1507-1515.
77. Clynes RA, Towers TL, Presta LG, et al.: Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2006;6:443.
78. Nahta R, Yu D, Hung MC, et al.: Mechanisms of disease: understanding resistance to Her2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006;3:269-280.
79. Pegram M, Hsu S, Lewis G, et al.: Inhibitory effects of combinations of HER-2/neu antibody and chem-otherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18:2241-2251.
80. Casalini P, Iorio M V, Galmozzi E, et al.: Role of HER receptors family in development and differentiation. J Cell Physiol 2004;200:343-350.
81. Fukazawa R, Miller TA, Kuramochi Y, et al.: Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt. J Mol Cell Cardiol 2003;35:1473-1479.
82. Perez EA, Rodeheffer R: Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004;22:322-329.
83. Piccart-Gebhart MJ, Proctet M, Leyland-Jones B, et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659-1672.
84. Romond EH, Perez EA, Bryant J, et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-1684.
85. Guarneri V, Lenihan DJ, Valero V, et al.: Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The M.D. Anderson Cancer Center experience. J Clin Oncol 2006;24:4107-4115.
86. Chen B, Peng X, Pentassuglia L, et al.: Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc Toxicol 2007;7:114-121.
87. Rajagopalan S, Politi PM, Sinha BK, et al.: Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res 1988;4:4766-4769.
88. Wiseman LR, Spencer CM: Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Drugs 1998;56:485-403.
89. Von Hoff D, Rozencweig M, Piccart M: The car-diotoxicity of anticancer agents. Sem Oncol 1982;9: 23-33.
90. Allan A: The cardiotoxicity of chemotherapeutic drugs. Sem Oncol 1992;19:529-542.
91. Keefe DL: Trastuzumab-associated cardiotoxicity. Cancer 2002;95:1592-600.
92. Jessup M, Abraham WT, Casey DE, et al.: Focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009; epub ahead of print.
93. Slamon D, Eiermann W, Robert N, et al.: BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and tras-tuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Breast Cancer Res Treat 2006;100(suppl 1):abstr 52.
94. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, et al.: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-820.
95. Al-Dasooqi N, Bowen JM, Gibson RJ, et al.: Trastu-zumab induces gastrointestinal side effects in Heroverexpressing breast cancer patients. Invest New Drugs 2009;27:173-178.
96. Roché H, Fumoleau P, Spielmann M, et al.: Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006; 24:5664-5671.
97. Martin M, Lluch A, Segui MA, et al.: Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxo-rubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 2006;17:1205-1212.
98. Jones S, Holmes FA, O'Shaughnessy J, et al.: Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxo-rubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 2009;27:1177-1183.